
Dutasteride Soft Capsules
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20234210
Indications:
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) with prostatic enlargement, reducing the risk of acute urinary retention (AUR) and BPH-related surgery.
Administration:
Adults (including the elderly):
The recommended dose is one capsule (0.5 mg) once daily, to be taken orally. The capsule should be swallowed whole and must not be chewed or opened, as the contents may irritate the oropharyngeal mucosa. It can be taken with or without food. Although symptom improvement may be observed early in treatment, the full therapeutic effect may take up to 6 months to achieve. No dose adjustment is required for elderly patients.
Renal impairment:
The effect of renal impairment on the pharmacokinetics of dutasteride has not been studied. However, no dose adjustment is anticipated for patients with renal impairment.
Hepatic impairment:
The effect of hepatic impairment on the pharmacokinetics of dutasteride has not been studied. Caution is advised when administering this medication to patients with mild to moderate hepatic impairment. The use of dutasteride is contraindicated in patients with severe hepatic impairment.
Specifications:
0.5mg x 7 tablets, 0.5mg x 14 tablets
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province

Mobile Version QR Code

WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.